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12th
Cirrhosis and Chronic Liver Disease is the 12th leading cause of death in the
United States

Introduction:
●

Cirrhosis is a heterogeneous disease of late stage progressive hepatic fibrosis

●

It is often an indolent disease
○
○
○

●

Often is discovered during a routine examination with laboratory or radiographic studies, or at
autopsy
Most patients remain asymptomatic until “decompensation”
Unfortunately, at that point, largely irreversible and poor prognosis

Preventive strategies can maximize time before liver transplantation or death for
those with early cirrhosis by avoiding further damage and mitigating comorbidity

Role as Primary Care Physicians...
●

The incidence of liver cirrhosis is expected to increase in the near future

●

PCPs play a key role in prevention, treatment, timely referrals to specialists and
multidisciplinary team members (dieticians, psychologists, etc.), collaborative
management, surveillance and home care of populations at risk!

Algorithm for the management of patients with (or with
suspected) liver cirrhosis in General Practice

Objectives:
●
●
●

Understand the morbidity and mortality associated with Cirrhosis in the United
States
Recognize etiologies and clinical presentation of cirrhosis
Identify decompensated cirrhosis and approaches to treatment and monitoring

Agenda:
●
●
●
●
●
●

Definition and Epidemiology
Etiologies
Clinical Presentation
Diagnosis and Evaluation/Classification
Management of Compensated Cirrhosis
Decompensated Cirrhosis & Complications
○
○
○
○
○
○

●
●

Portal Hypertension
Varices
Ascites
SBP
Hepatorenal Syndrome
Hepatic Encephalopathy

Secondary Prevention and Long Term Management
Conclusions

What is
Cirrhosis?

Deﬁnition:
Hepatic parenchymal necrosis and an inflammatory response to the underlying cause
→ chronic hepatocellular injury
→ subsequent hepatic repair mechanisms lead to irreversible fibrosis and
abnormal tissue architecture (nodular regeneration)
→ which ultimate results in impaired liver function

Number of adults with diagnosed liver
disease: 4.5 million

Impact of Liver
Disease in the
US

Percent of adults with diagnosed liver
disease: 1.8%

Deaths per 100,000 population: 12.8

More common in adults ages 45-54

Epidemiology of Cirrhosis:
Prevalence: approx. 0.27%* in U.S. adults
Sex: ♂ > ♀ (2:1)
Responsible for approx. 1–2% of all deaths in the United States; most deaths occurring
in the fifth to sixth decade of life

(likely an underestimate)*

Health Disparities related to Cirrhosis:
●

Highest prevalence among non-Hispanic Blacks, Mexican Americans, those living
below the poverty level, and those with less than a 12th grade education

●

Additionally, there are disparities associated with referral to transplant centers and
receipt of donor organs

●

Public health eﬀorts are needed to reduce this disease burden, particularly among
racial/ethnic minorities and individuals at lower socioeconomic status

Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin
Gastroenterol. 2015; 49(8): 690-696.

Costs to the Healthcare System:
●

Cirrhosis and advanced liver disease cost the United States between $12 billion and
$23 billion dollars in health care expenses annually

●

Additionally, annual costs increase with decompensation; for instance:
○
○
○
○
○

●

$2,400 for the treatment of diuretic-sensitive ascites
$24,800 for the treatment of diuretic-refractory ascites
$25,600 for the treatment of variceal hemorrhage
$16,400 for the treatment of hepatic encephalopathy
$44,200 for the treatment of hepatocellular carcinoma.

In some sources, cited as “ranks eighth in economic cost among the major
illnesses”

What Causes
Cirrhosis?

Etiologies:

Wolf. Medscape.
emedicine.medscape.com/article/185856-overview?src=emailthis#a4

How does
cirrhosis present
clinically?

Name all of the main clinical features
of cirrhosis of the liver.

Clinical Presentation

Common cutaneous manifestations of cirrhosis

Photo Credit: DermNet NZ

Early Findings:
Lab Findings:
●
●
●
●
●

May be normal!
Incidentally noted elevated liver enzymes (AST, ALT, bilirubin)
Low albumin (<3.5g/dL)
Thrombocytopenia (<160K)
Prolonged Prothrombin Time (PT)/Elevated INR

Other labs to order include: Alkaline Phosphatase, Gamma-glutamyl transferase, viral
hepatitis serologies, ferritin, transferrin saturation, fasting lipid and a1c (if risk factors
for NAFLD exist), consider studies for autoimmune hepatitis, ANA, Anti-SMAb, or others
based on risk factors and clinical findings

Noninvasive Evaluation:
●

Biomarkers (e.g. FibroSure) and non-proprietary, serum based calculators (e.g. AST
to platelet ratio index [APRI], NAFLD fibrosis score, etc.)

●

Ultrasonography
○
○

Low cost, easily accessible
Sensitive and specific for steatosis, but may miss fibrosis and cirrhosis (only 40-57% sensitive)
U/S: advanced cirrhotic liver appears to
be nodular, irregular, and contracted with
relatively enlarged caudate lobe (C) and
lateral segment (L) of the left lobe. Fatty
infiltration and fibrosis give a coarse
echotexture of the liver parenchyma.

Transient Elastography:
●
●

Now more widely available; only takes 5 minutes!

●

U/S technique performed w/ specialized machine (Fibro-Scan)
to determine liver stiﬀness by measuring velocity of
low-frequency elastic shear waves propagating through the
liver

●

81% sensitive and 88% specific for detecting liver fibrosis and
cirrhosis

●
●

Less accurate at distinguishing between stages of liver disease

Rapidly replacing biopsy as preferred method for fibrosis
staging

Less reliable in patients w/ obesity, ascites, excessive EtOH
intake, extrahepatic cholestasis, acute hepatic inflammation
Transient Elasticity

Liver Biopsy Indications:
●
●
●

Concern for fibrosis remains after indeterminate or conflicting clinical, lab and
imaging results
Transient Elastography is not suitable
To clarify etiology of disease after inconclusive noninvasive evaluation

Still the reference standard in diagnosing cirrhosis, however a 20% error rate still occurs
in fibrosis staging and use of noninvasive methods has become increasingly common in
clinical practice

Classiﬁcation:

Staging/Risk Stratiﬁcation:

Child-Pugh score
Points

1

2

3

Serum albumin g/dL

> 3.5

2.8–3.5

< 2.8

Serum bilirubin mg/dL

< 2.0

2.0–3.0

> 3.0

INR

< 1.7

1.7–2.3

> 2.3

Ascites

None

Mild

Moderate

Hepatic encephalopathy

None

Minimal

Advanced

Child-Pugh class A: 5–6 points; Child-Pugh class B: 7–9 points; Child-Pugh class C: 10–15 points

Management and Treating
Complications...

Management and Prevention of
Complications:
●

primary goals are to prevent cirrhosis complications, liver decompensation, and
death

●

accomplished with rigorous prevention counseling (see next slide), monitoring,
and management by primary care physicians, in consultation with subspecialists
as needed

Routine Monitoring:
●

Every 6 months to recalculate CP and MELD scores
○
○
○
○

●

BMP
LFT
CBC
PT/INR

Refer for liver transplantation evaluation if:
○ MELD ≥ 15
○ Ascites
○ Hepatic Encephalopathy
○ Variceal Hemorrhage

Disease Progression:

Portal Hypertension:
●
●

PH is the initial and main consequence of cirrhosis and is responsible for the majority of its
complications.
Hepatic Venous Pressure Gradient (HVPG) is the gold standard for assessing severity of PH.
It’s an estimate of the pressure diﬀerential between the portal vein and IVC.

Varices:
●

Portal hypertension predisposes patients with cirrhosis to develop esophageal
varices
○

○

●

Gastroesophageal varices (GEV) are present in approximately 50% of patients with cirrhosis, but this
depends on the clinical stage.
■ In patients with compensated cirrhosis, GEV are present in 30%-40%, whereas they can be
present in up to 85% of patients with decompensated cirrhosis
Patients with varices have a one in three chance of developing a variceal bleed in the two years after
diagnosis, with a 20% to 40% mortality rate per episode.

Endoscopy is the preferred screening method for esophageal varices
○

○

Many experts and guidelines recommend screening all patients with cirrhosis; however, newer
recommendations suggest targeted screening of patients with clinically significant portal
hypertension.
Every 1-2 years if small varices found and every 2-3 years if no varices found

Variceal Hemorrhage
●

Occurance rate of variceal hemorrhage varies depending on the severity of the liver
disease, size of varices, and presence of variceal wall thinning (red wale marks)
○

●

~10-15% per year

Six-week mortality (the now-recognized primary endpoint to assess impact of
therapies for acute hemorrhage) ranges between 15-25%!

Management of Varices and Variceal
Hemorrhage
●

Primary Prophylaxis (see next slide)

●

If bleeding, acute treatment goals include:
○
○
○

●

hemodynamic resuscitation
treatment of active bleeding
prevention of rebleeding
■ Band ligation is the standard for the control of variceal bleeding.
■ If banding is diﬀicult because of continued variceal bleeding, endoscopic sclerotherapy with
vasoconstrictors (e.g., octreotide) or a Sengstaken-Blakemore tube insertion (with adequate
airway protection) may be used until TIPS or surgical treatment can be arranged.

Recurrent or Treatment Resistant Hemorrhage:
○
○

Pursue TIPS (transjugular intrahepatic portosystemic shunt) to lower portal pressure
Can d/c beta blockers

TIPS
Procedure
●

●

A needle catheter inserted via the internal jugular vein → passed along to hepatic
vein → pierced through liver parenchyma to intrahepatic branch of the portal vein →
expandable metal stent is placed → side-to-side portocaval shunt
Assures blood drainage from the portal to the systemic system bypassing the liver,
thus lowering portal pressure

Several contraindications...

Ascites:
●

Abnormal accumulation of fluid in the peritoneal cavity
○

●

Ddx includes conditions causing portal hypertension and/or hypoalbuminemia

If ascites origin in unclear, can perform paracentesis and ascitic fluid assessment

Treating Ascites in Cirrhosis:
●

Sodium Restriction!
○

●
●
●

Spironolactone
Furosemide (if massive ascites)
Albumin
○

●

MAX 2000mg DAILY

Administer if > 5L fluid removed during paracentesis

Fluid Restriction?
○

If serum sodium is less than 125 mEq per L

Need to monitor potassium and creatinine
If refractory or diuretics contraindicated → large volume paracentesis and
consideration of TIPS

Spontaneous Bacterial Peritonitis:
●

Infx of peritoneal fluid. A common complication of uncontrolled ascites
○

●
●
●

Caused by translocation of gut bacteria or sepsis

Presentation: signs of peritonitis, SIRS, worsening liver fx, hepatic encephalopathy,
renal failure, shock, GI bleed…However, may be asymptomatic
Diagnosed by PMN >250/mm³ or + Gram stain/culture on ascitic fluid
Historically, HIGH MORTALITY (related to renal failure); reduced to ~ 20% with early
diagnosis & treatment

Treatment for SBP
Start empiric tx (e.g. cefoxitime) and use ascitic culture to guide therapy, however pt’s
may have culture-negative SBP
- May use ciprofloxacin unable to use cephalosporin
- Consideration of resistance patterns (e.g. if pt on fluoroquinolone for ppx)
Most cases of SBP are due to gut bacteria such as E. coli and Klebsiella, though
streptococcal and staphylococcal infections can also occur
Albumin should be administered from day 1-3 of treatment if Cr>1, BUN >30, tBili >4 to
reduce risk of renal failure
d/c bb once SBP has developed (associated w/ increased mortality)

SBP - prophylactic antibiotics?
Clinical Question:
Should antibiotic prophylaxis be used for hospitalized patients with cirrhosis and upper
gastrointestinal bleeding?

Evidence-Based Answer:
Antibiotics should be used for prophylaxis in hospitalized patients with cirrhosis and
upper gastrointestinal bleeding. (Strength of Recommendation: A, based on consistent
results from two meta-analyses and a cohort study.)
Prophylaxis reduces all-cause mortality by 21%, as well as bacterial infections and
rebleeding.

Hepatorenal Syndrome:
●
●

Renal dysfunction secondary to reduction in renal blood flow in the setting of
cirrhosis and portal hypertension
Mainstay of treatment is vasopressor therapy with albumin
○
○

●
●

Attempt to reverse splanchnic vasodilation and improve renal blood flow
Primarily terlipressin and noradrenalin

Limited role for Renal replacement therapy or TIPS
Leads to death in the absence of liver transplantation :(

RI = resistive indices

Hepatic Encephalopathy:
●
●

Brain dysfunction caused by liver insuﬀiciency and failure to detoxify NH3
Wide spectrum of neurologic/ psychiatric abnormalities from mild cognitive loss to
confusion to coma
○
○

●

Onset may be gradual or sudden
May include movement problems, changes in mood, confusion, disordered sleep, or changes in
personality

Pitfalls: High blood ammonia levels alone add no diagnostic, staging, or prognostic
value . . .

Treatment options for Hepatic
Encephalopathy

Other Complications of Cirrhosis
●
●
●
●
●
●

bone diseases, such as Osteoporosis
Biliary disease and Gallstones
Malabsorption and Malnutrition
Bruising and Bleeding easily
Sensitivity to Medicines (limited drug metabolism)
Insulin resistance and Type 2 diabetes

Secondary Prevention

Preventing Superimposed Liver Insults:
●
●
●

Avoidance of hepatotoxins
Medication Adjustments
Vaccinations

Weight Reduction/
Obesity Management:

Careful dietary counseling and encouragement
of weight loss is vital to reducing mortality

Dietary Counseling

Surveillance
Assess Cirrhosis Patients for Hepatocellular Carcinoma:
- AASLD recommends U/S + α‐fetoprotein every 6-12 months
-

Data is currently lacking**

Monitoring for patients with Varices:
- Upper Endoscopy every 1-2 years
- Newer guidelines suggest targeted screening for esophageal varices in patients
with clinically significant portal hypertension rather than screening all patients
with cirrhosis

Liver Transplantation
●

Organ transplantation
has become standard of
care for patients with
end-stage liver, kidney,
lung and heart disease

●

Liver is the second most
commonly transplanted
organ

●

90% 1 yr and 80% 5 yr
survival

Conclusions:
●

Liver cirrhosis has an increasing prevalence worldwide, which matches the
increase in viral hepatitis infection and metabolic steatohepatitis

●

Liver transplantation is standard of care for end stage liver disease, however access
is limited

●

PCP’s role in prevention, surveillance, and secondary prevention to reduce
decompensation are vital to reducing morbidity and mortality from chronic liver
disease
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